Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy
Shots: The P-II CONVEY withdrawal study evaluates efficacy & safety of vixotrigine (200/350 mg, bid) vs PBO in 265 patients with SFN for 12wks. The study met its 1EPs i.e., 200mg dose showed a reduction in mean ADP & worst daily pain score @12wks. while 350mg dose did not meet its 1EPs of mean change […]